Organics processing firm says its ReCirculate food waste-content potting soil and compost will be available in retail stores ...

Fred Sousa, VP of retail sales at Denali, will join Louise Fritjofsson, CEO and co-founder of Martie Inc., for a session on ...

Denali, the nation’s leading recycler of organics, today introduced ReCirculate – its compost and organic potting soil ...

Sanofi (NASDAQ:SNY) has failed in another mid-stage trial for DNL788, an experimental therapy developed with Denali Therapeutics (NASDAQ:DNLI) for neurological conditions such as amyotrophic ...

A car rebuild expert found a GMC Sierra Denali with a salvage title, sitting abandoned in an auction yard, looking pathetic. The pickup truck is listed as damaged by fire, but was it really ...

Related: Up Close With the 2024 GMC Sierra EV Denali Edition 1 There is one major development for the 2025 GMC Sierra EV: The introduction of a new, smaller battery. That this smaller pack is ...

The 2025 GMC Sierra EV Denali has popped up on the company's website. It's the only 2025 model listed, and it offers nearly $10,000 in savings versus the sold-out 2024 Edition 1. GMC has released ...

In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Denali Therapeutics (DNLI – Research Report). The company’s shares closed yesterday at $25.74. According to ...

The 2024 GMC Sierra EV Denali Edition 1 is still a rare sight on US roads, but that hasn’t stopped GM from rolling out the 2025 version with up to 440 miles of range … and a base price that ...

On Friday, Denali Therapeutics Inc. (NASDAQ:DNLI) maintained its Buy rating from TD Cowen, despite recent clinical trial results. The phase 2 study evaluating DNL788, a small molecule RIPK1 ...

GMC's Sierra EV Denali has two battery options and a lower starting price for 2025 All Sierra EV Denalis continue to deliver a maximum 754 hp More models including a rugged AT4 arrive next year ...

On Friday, Denali Therapeutics Inc. (NASDAQ:DNLI) maintained its Buy rating from TD Cowen, despite recent clinical trial results. The phase 2 study evaluating DNL788, a small molecule RIPK1 inhibitor, ...